ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium
ALX Oncology (Nasdaq: ALXO) announced that updated results from its Phase 2 ASPEN-06 clinical trial will be presented at the 2025 ASCO Gastrointestinal Cancers Symposium. The trial evaluates evorpacept, a CD47-blocking therapeutic, in combination with trastuzumab, CYRAMZA® (ramucirumab) and paclitaxel for treating HER2-positive gastric/gastroesophageal junction cancer patients who previously received anti-HER2 therapy.
The presentation will be delivered by Dr. Kohei Shitara from the National Cancer Center Hospital East in Japan on January 23, 2025. The study results will be presented during the Rapid Oral Abstract Session focusing on Cancers of the Esophagus and Stomach.
ALX Oncology (Nasdaq: ALXO) ha annunciato che i risultati aggiornati del suo trial clinico di Fase 2 ASPEN-06 saranno presentati al Simposio delle Neoplasie Gastrointestinali ASCO 2025. Il trial valuta evorpacept, una terapia che blocca il CD47, in combinazione con trastuzumab, CYRAMZA® (ramucirumab) e paclitaxel per il trattamento di pazienti con cancro gastrico/giunzione gastroesofagea positivo al HER2 che hanno precedentemente ricevuto terapia anti-HER2.
La presentazione sarà effettuata dal Dr. Kohei Shitara del National Cancer Center Hospital East in Giappone il 23 gennaio 2025. I risultati dello studio saranno presentati durante la Sessione di Abstract Oral Rapida focalizzata sui Tumori dell'Esofago e dello Stomaco.
ALX Oncology (Nasdaq: ALXO) anunció que los resultados actualizados de su ensayo clínico de Fase 2 ASPEN-06 se presentarán en el Simposio de Cánceres Gastrointestinales ASCO 2025. El ensayo evalúa evorpacept, una terapia que bloquea CD47, en combinación con trastuzumab, CYRAMZA® (ramucirumab) y paclitaxel para tratar a pacientes con cáncer gástrico/junción gastroesofágica HER2-positivo que han recibido previamente terapia anti-HER2.
La presentación será realizada por el Dr. Kohei Shitara del National Cancer Center Hospital East en Japón el 23 de enero de 2025. Los resultados del estudio se presentarán durante la Sesión de Resúmenes Orales Rápidos centrada en los Cánceres del Esófago y el Estómago.
ALX Oncology (Nasdaq: ALXO)는 2상 ASPEN-06 임상 시험의 업데이트된 결과가 2025 ASCO 위장관 암 심포지엄에서 발표될 것임을 발표했습니다. 이 시험은 evorpacept라는 CD47 차단 치료제를 trastuzumab, CYRAMZA®(ramucirumab), 그리고 paclitaxel과 병용하여 이전에 항-HER2 치료를 받은 HER2 양성 위/위장접합부 암 환자들을 치료하는 것을 평가합니다.
발표는 일본의 National Cancer Center Hospital East의 Kohei Shitara 박사에 의해 2025년 1월 23일에 진행될 예정입니다. 연구 결과는 식도와 위의 암에 초점을 맞춘 신속 구두 초록 세션에서 발표됩니다.
ALX Oncology (Nasdaq: ALXO) a annoncé que des résultats mis à jour de son essai clinique de Phase 2 ASPEN-06 seront présentés lors du Symposium ASCO sur les Cancers Gastro-Intestinaux 2025. L'essai évalue l'evorpacept, un traitement bloquant le CD47, en association avec le trastuzumab, le CYRAMZA® (ramucirumab) et le paclitaxel pour traiter des patients atteints de cancer gastrique/jonction gastro-œsophagienne HER2-positif ayant déjà bénéficié d'une thérapie anti-HER2.
La présentation sera faite par le Dr Kohei Shitara du National Cancer Center Hospital East au Japon le 23 janvier 2025. Les résultats de l'étude seront présentés lors de la session de résumés oraux rapides axée sur les cancers de l'œsophage et de l'estomac.
ALX Oncology (Nasdaq: ALXO) gab bekannt, dass aktualisierte Ergebnisse aus der Phase-2-ASPEN-06-Studie auf dem ASCO Symposion für gastrointestinale Krebserkrankungen 2025 vorgestellt werden. Die Studie bewertet evorpacept, ein CD47-blockierendes Therapeutikum, in Kombination mit Trastuzumab, CYRAMZA® (Ramucirumab) und Paclitaxel zur Behandlung von HER2-positiven Patienten mit Magen-/Gastroösophagealkrebs, die zuvor eine Anti-HER2-Therapie erhalten haben.
Die Präsentation wird am 23. Januar 2025 von Dr. Kohei Shitara vom National Cancer Center Hospital East in Japan gehalten. Die Studienergebnisse werden während der Rapid Oral Abstract Session zu Ösophagus- und Magenkrebs präsentiert.
- Selection for oral presentation at major medical conference indicates potential significance of trial results
- Trial advances company's development in HER2-positive gastric cancer treatment
- None.
Insights
SOUTH SAN FRANCISCO, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives, today announced that the updated results from its Phase 2 ASPEN-06 clinical trial have been accepted for oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, which will be held in San Francisco from January 23 - 25, 2025.
ASPEN-06 is a randomized, multi-center, international trial (NCT05002127) evaluating evorpacept, ALX Oncology’s investigational CD47-blocking therapeutic that uniquely combines a high-affinity CD47-binding domain with an inactivated proprietary Fc domain, in combination with trastuzumab, CYRAMZA® (ramucirumab) and paclitaxel (collectively, TRP) against TRP alone for the treatment of patients with HER2-positive gastric/gastroesophageal junction cancer, where all patients had received an anti-HER2 agent in prior lines of therapy.
The updated results from the ASPEN-06 study will be detailed in the following oral presentation:
Title: Final analysis of the randomized phase 2 part of the ASPEN-06 study: A phase 2/3 study of evorpacept (ALX148), a CD47 myeloid checkpoint inhibitor, in patients with HER2-overexpressing gastric/gastroesophageal cancer (GC)
Abstract Number: 332
Presenter: Kohei Shitara, MD, Director of the Department of Gastrointestinal Oncology, at National Cancer Center Hospital East, Kashiwa in Japan
Presentation Date and Time: Thursday, January 23, 2025, from 9:15 a.m. – 10:00 a.m. PST
Session Information: Rapid Oral Abstract Session A: Cancers of the Esophagus and Stomach
Location: Level 2 Ballroom
Copies of the presentations will be available on the Publications section of ALX Oncology’s website following presentation at the meeting.
About ALX Oncology
ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives. ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. More information is available at www.alxoncology.com and on LinkedIn @ALX Oncology.
FAQ
What is the Phase 2 ASPEN-06 trial testing for ALXO's evorpacept?
When will ALXO present the ASPEN-06 trial results at ASCO GI 2025?
What is evorpacept's mechanism of action in ALXO's cancer treatment?
Who will present ALXO's ASPEN-06 trial results at ASCO GI 2025?
